Patient Suffers Brain Damage from Anesthesia Reversal Agents

Anesthesia ExpertThis case involves a patient with a past medical history of diabetes, morbid obesity, and renal failure. The patient had been on dialysis and had maintained fairly well, however he required a renal transplant. The transplant procedure itself was a success, however, once reversal agents for his anesthesia were administered, the patient’s condition rapidly deteriorated. Two drugs were administered – Neospigmine and Glycopyrolate. These reversal agents are generally administered in a 5:1 ratio; however, the physicians caring for this patient administered a 5:6 ratio of the aforementioned combination. The patient’s heart rate slowed and he suffered cardiac arrest, along with severe brain injury. As a result of these injuries, the patient is now in a permanent vegetative state and unable to care for his wife and 5 children. Prior to his injuries, the patient had been working full time, managing a successful career and full family life.

Question(s) For Expert Witness

  • 1. Do you have experience preparing the reversal agents mentioned above, in the 5:1 ratio?
  • 2. Should the ratio have been reduced to 5:6?
  • 3. Have you ever served as an expert witness on a case involving reversal agents?
  • 4. How often do you administer reversal agents for transplant patients?

Expert Witness Response E-008133

I have experience with reversal agents and use them daily in my practice. I cover many types of generalist cases including anesthesia for solid organ transplantation. I typically use reversal agents for transplant patients. Regardless, when reversal is needed and timing is appropriate, I usually prepare reversal doses of neostigmine of approximately 0.07 mg/kg and glycopyrrolate of approximately 10 mcg/kg and administer them concurrently. If this 47 year old patient were 70 kg, then the dose I would use would be approximately 4.9 mg neostigmine / 0.7 mg glycopyrrolate given TOF monitoring. This is an approximate 7:1 ratio. Decreasing the dose of glycopyrrolate may lead to bradycardia which can be potentially dangerous.

Contact this expert witness